Literature DB >> 24969691

MicroRNA-124 regulates TGF-α-induced epithelial-mesenchymal transition in human prostate cancer cells.

Wei Qin1, Yujia Pan2, Xiulan Zheng1, Dong Li1, Jingyi Bu1, Chunyan Xu1, Jiebing Tang3, Rongjun Cui4, Ping Lin1, Xiaoguang Yu1.   

Abstract

Transforming growth factor-α (TGF-α) is upregulated in advanced stages of prostate cancer and strongly correlated with metastasis. However, the effect of TGF-α on epithelial-mesenchymal transition (EMT) in prostate cancer and the underlying mechanisms remain unclear. Recently, microRNAs have emerged as new regulators of EMT. This study found that treatment of DU145 cells with TGF-α suppressed the expression of epithelial marker E-cadherin and increased the expression of mesenchymal marker Vimentin as well as changed the cell morphology from cobblestone shape to spindle shape. The level of miR-124 was downregulated by TGF-α in several different cancer cell lines. Enforced expression of miR-124 abolished TGF-α-induced EMT. Slug was proven to be a target of miR-124 and mediated the inhibitory effect of miR-124 on TGF-α-induced EMT. Furthermore, overexpression of miR-124 reduced the migratory and invasive capacity of TGF-α-treated DU145 cells. In conclusion, our findings suggest that miR-124 inhibits TGF-α-induced EMT in DU145 cells by targeting Slug. Thus, miR-124 may be a potential target for prostate cancer therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24969691     DOI: 10.3892/ijo.2014.2506

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  16 in total

1.  Evaluation of miR-29c, miR-124, miR-135a and miR-148a in predicting lymph node metastasis and tumor stage of gastric cancer.

Authors:  Li Liu; Jia-Xiang Ye; Yu-Zhou Qin; Qi-Huang Chen; Lian-Ying Ge
Journal:  Int J Clin Exp Med       Date:  2015-12-15

2.  Paraquat but not diquat induces TGF-β expression and thus activates calcium-NFAT axis for epithelial-mesenchymal transition.

Authors:  Wenyu Yang; Xinrun Ma; Yong Zhu; Xiaoxiao Meng; Rui Tian; Zhengfeng Yang
Journal:  Toxicol Res (Camb)       Date:  2021-06-17       Impact factor: 2.680

Review 3.  The Role of MicroRNA in the Regulation of Tumor Epithelial-Mesenchymal Transition.

Authors:  Jing Feng; Shaofan Hu; Keli Liu; Guiyin Sun; Yiguo Zhang
Journal:  Cells       Date:  2022-06-21       Impact factor: 7.666

4.  miR-124 Regulates the Epithelial-Restricted with Serine Box/Epidermal Growth Factor Receptor Signaling Axis in Head and Neck Squamous Cell Carcinoma.

Authors:  Manchao Zhang; Longzhu Piao; Jharna Datta; James C Lang; Xiujie Xie; Theodoros N Teknos; Anna K Mapp; Quintin Pan
Journal:  Mol Cancer Ther       Date:  2015-07-30       Impact factor: 6.261

5.  MiR-124 suppresses cell motility and adhesion by targeting talin 1 in prostate cancer cells.

Authors:  Wei Zhang; Ye-Qing Mao; Hua Wang; Wen-Juan Yin; Shao-Xing Zhu; Wei-Cheng Wang
Journal:  Cancer Cell Int       Date:  2015-05-06       Impact factor: 5.722

Review 6.  EGF receptor ligands: recent advances.

Authors:  Bhuminder Singh; Graham Carpenter; Robert J Coffey
Journal:  F1000Res       Date:  2016-09-08

Review 7.  MicroRNAs and epithelial-mesenchymal transition in prostate cancer.

Authors:  Kirandeep Sekhon; Nathan Bucay; Shahana Majid; Rajvir Dahiya; Sharanjot Saini
Journal:  Oncotarget       Date:  2016-10-11

8.  The correlation between microRNA490-3p and TGFα in endometrial carcinoma tumorigenesis and progression.

Authors:  Kai-Xuan Sun; Ying Chen; Shuo Chen; Bo-Liang Liu; Miao-Xiao Feng; Zhi-Hong Zong; Yang Zhao
Journal:  Oncotarget       Date:  2016-02-23

9.  miR-124 and miR-506 inhibit colorectal cancer progression by targeting DNMT3B and DNMT1.

Authors:  Zhiheng Chen; Shaojun Liu; Li Tian; Minghao Wu; Feiyan Ai; Wuliang Tang; Lian Zhao; Juan Ding; Liyang Zhang; Anliu Tang
Journal:  Oncotarget       Date:  2015-11-10

10.  MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-α.

Authors:  Shuo Chen; Kai-Xuan Sun; Bo-Liang Liu; Zhi-Hong Zong; Yang Zhao
Journal:  Mol Cancer       Date:  2016-02-02       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.